A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Inclusion criteria

• Males and females (of non-childbearing potential) between 18 and 55 years of age, inclusive
• Body weight > 55.0 kg and body mass index within 18.0 to 32.0 kg/m2, inclusive
• Normal cardiac structure and function, or if abnormalities are present, they are deemed not clinically significant
• Normal to high left ventricular ejection fraction.
• Normal electrocardiogram (ECG) or, if abnormalities are present, they are deemed not clinically significant
• Clinical laboratory findings within normal range
• Negative hepatitis panel (including hepatitis B surface antigen and hepatitis C antibody), and negative human immunodeficiency virus antibody screens
• Willing and able to refrain from strenuous exercise (eg, activity which could be expected to cause muscle soreness)
• For Arms 5 and 6 only: Subject is a CYP2D6 poor metabolizer

Exclusion criteria

• History of any significant illness or disorder
• History of stomach or intestinal surgery or resection (appendectomy, hernia repair, and/or cholecystectomy will be allowed)
• A clinically significant illness within 4 weeks of Check-in
• Inability to swallow capsules or tablets
• History of or current substance abuse (drug or alcohol), known drug or alcohol dependence within the last 2 years prior to Screening, or positive test for drugs of abuse during the screening period
• Use of any tobacco-containing or nicotine-containing products within 3 months prior to Check-in
• Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 30 days prior to Check-in
• Any blood donation within 60 days of dosing, plasma donation within 30 days of dosing, or receipt of blood products within 2 months prior to Check-in